These conditions typically resolve within weeks to months after statin discontinuation. These forms of statin-induced myopathy vary distinctly from another clinical entity termed statin-associated immune-mediated necrotizing myopathy (IMNM), characterized by variable degrees of proximal muscle weakness, markedly elevated CK levels, evidence of muscle necrosis on histopathology, and anti-HMGCR (anti-hydroxy-methyl-glutaryl coA reductase) antibodies, suggesting an autoimmune-related phenomenon [3]. The gene discussed is HMGCR; the disease is myopathy.